Anirvan Ghosh is Chief Executive Officer of UNITY Biotechnology, a clinical-stage company focused on developing medicines to slow age-associated diseases. Prior to this, he led a team of 350 scientists and clinicians at Biogen. His team was responsible for preclinical, and clinical Phase 1 and Phase 2 studies in all of the disease areas at Biogen. Ghosh was also involved in expanding the portfolio through key partnerships, including acquisition of early-stage assets in Alzheimer’s Disease, Schizophrenia, and Ophthalmology, and several multi-asset platform collaborations.
EARLY LIFE AND EDUCATION
AWARDS AND RECOGNITIONS